A patient who begins GLP-1 therapy often experiences significant fatigue, nausea, and reduced appetite in the early weeks
Built on a 39-amino acid GIP backbone, it simultaneously activates three distinct receptor systems: GLP-1, GIP, and glucagon receptors
After years of development, a synthetic version of exendin-4, known as exenatide and marketed as Byetta, was approved by the FDA in 2005
Our B12 injections can help to protect your cardiovascular health
But our natural GLP-1 satiety mechanism fails, because most food components are rapidly digested and absorbed at the beginning of our small intestine, and dont make it way down to the end of the small intestine where our GLP-1-secreting cells are concentrated